Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins (original) (raw)

• Wang, J. C. & Dick, J. E. Cancer stem cells: lessons from leukemia. Trends Cell Biol. 15, 494–501 (2005).
  CAS PubMed Google Scholar
• Clarke, M. F. et al. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 66, 9339–9344 (2006).
  Article CAS PubMed Google Scholar
• Campbell, L. L. & Polyak, K. Breast tumor heterogeneity: cancer stem cells or clonal evolution? Cell Cycle 6, 2332–2338 (2007).
  CAS PubMed Google Scholar
• Pardal, R., Clarke, M. F. & Morrison, S. J. Applying the principles of stem-cell biology to cancer. Nature Rev. Cancer 3, 895–902 (2003).
  CAS Google Scholar
• Hill, R. P. Identifying cancer stem cells in solid tumors: case not proven. Cancer Res. 66, 1891–1895; discussion 1890 (2006).
  CAS PubMed Google Scholar
• Somervaille, T. C. et al. Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell 4, 129–140 (2009).
  CAS PubMed PubMed Central Google Scholar
• Kennison, J. A. The Polycomb and trithorax group proteins of Drosophila: trans-regulators of homeotic gene function. Annu. Rev. Genet. 29, 289–303 (1995).
  CAS PubMed Google Scholar
• Simon, J. Locking in stable states of gene expression: transcriptional control during Drosophila development. Curr. Opin. Cell Biol. 7, 376–385 (1995).
  CAS PubMed Google Scholar
• Pirrotta, V. Chromatin-silencing mechanisms in Drosophila maintain patterns of gene expression. Trends Genet. 13, 314–318 (1997).
  CAS PubMed Google Scholar
• Schuettengruber, B., Chourrout, D., Vervoort, M., Leblanc, B. & Cavalli, G. Genome regulation by polycomb and trithorax proteins. Cell 128, 735–745 (2007).
  CAS PubMed Google Scholar
• Muller, J. & Verrijzer, P. Biochemical mechanisms of gene regulation by polycomb group protein complexes. Curr. Opin. Genet. Dev. 19, 150–158 (2009).
  PubMed Google Scholar
• Kerppola, T. K. Polycomb group complexes-many combinations, many functions. Trends Cell Biol. 19, 692–704 (2009).
  CAS PubMed PubMed Central Google Scholar
• Simon, J. A. & Kingston, R. E. Mechanisms of polycomb gene silencing: knowns and unknowns. Nature Rev. Mol. Cell Biol. 10, 697–708 (2009).
  CAS Google Scholar
• Bracken, A. P. & Helin, K. Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nature Rev. Cancer 9, 773–784 (2009). This Review highlights the intriguing role of cell fate transcription factors and long non-coding RNAs in the regulation of PcG function in cancer.
  CAS Google Scholar
• Breen, T. R. & Harte, P. J. Molecular characterization of the trithorax gene, a positive regulator of homeotic gene expression in Drosophila. Mech. Dev. 35, 113–127 (1991).
  CAS PubMed Google Scholar
• Orlando, V. & Paro, R. Chromatin multiprotein complexes involved in the maintenance of transcription patterns. Curr. Opin. Genet. Dev. 5, 174–179 (1995).
  CAS PubMed Google Scholar
• Brock, H. W. & van Lohuizen, M. The Polycomb group - no longer an exclusive club? Curr. Opin. Genet. Dev. 11, 175–181 (2001).
  CAS PubMed Google Scholar
• Jones, P. A. & Baylin, S. B. The epigenomics of cancer. Cell 128, 683–692 (2007).
  CAS PubMed PubMed Central Google Scholar
• Levine, S. S., King, I. F. G. & Kingston, R. E. Division of labor in Polycomb group repression. Trends Biochem. Sci. 29, 478–485 (2004).
  CAS PubMed Google Scholar
• Sparmann, A. & van Lohuizen, M. Polycomb silencers control cell fate, development and cancer. Nature Rev. Cancer 6, 846–856 (2006).
  CAS Google Scholar
• Cao, R. et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298, 1039–1043 (2002).
  CAS PubMed Google Scholar
• Orlando, V. Polycomb, epigenomes, and control of cell identity. Cell 112, 599–606 (2003).
  CAS PubMed Google Scholar
• Cao, R. & Zhang, Y. SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. Mol. Cell 15, 57–67 (2004).
  CAS PubMed Google Scholar
• Sing, A. et al. A vertebrate Polycomb response element governs segmentation of the posterior hindbrain. Cell 138, 885–897 (2009).
  CAS PubMed Google Scholar
• Woo, C. J., Kharchenko, P. V., Daheron, L., Park, P. J. & Kingston, R. E. A region of the human HOXD cluster that confers polycomb-group responsiveness. Cell 140, 99–110 (2010). References 24 and 25 provide the first functional evidence for the presence of PREs in mammals.
  CAS PubMed PubMed Central Google Scholar
• Levine, S. S. et al. The core of the polycomb repressive complex is compositionally and functionally conserved in flies and humans. Mol. Cell. Biol. 22, 6070–6078 (2002).
  CAS PubMed PubMed Central Google Scholar
• Allis, C. D. Jenuwein, T. & Reinberg, D. Epigenetics (Cold Spring Harbor Lab. Press, Cold Spring Harbor, New York, 2007).
  Google Scholar
• Wang, H. et al. Role of histone H2A ubiquitination in Polycomb silencing. Nature 431, 873–878 (2004).
  CAS PubMed Google Scholar
• Cao, R., Tsukada, Y. & Zhang, Y. Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing. Mol. Cell 20, 845–854 (2005).
  CAS PubMed Google Scholar
• Francis, N. J., Kingston, R. E. & Woodcock, C. L. Chromatin compaction by a polycomb group protein complex. Science 306, 1574–1577 (2004).
  CAS PubMed Google Scholar
• Dellino, G. I. et al. Polycomb silencing blocks transcription initiation. Mol. Cell 13, 887–893 (2004).
  CAS PubMed Google Scholar
• Papp, B. & Muller, J. Histone trimethylation and the maintenance of transcriptional ON and OFF states by trxG and PcG proteins. Genes Dev. 20, 2041–2054 (2006).
  CAS PubMed PubMed Central Google Scholar
• Stock, J. K. et al. Ring1-mediated ubiquitination of H2A restrains poised RNA polymerase II at bivalent genes in mouse ES cells. Nature Cell Biol. 9, 1428–1435 (2007).
  CAS PubMed Google Scholar
• Ku, M. et al. Genomewide analysis of PRC1 and PRC2 occupancy identifies two classes of bivalent domains. PLoS Genet. 4, e1000242 (2008).
  PubMed PubMed Central Google Scholar
• Schoeftner, S. et al. Recruitment of PRC1 function at the initiation of X inactivation independent of PRC2 and silencing. EMBO J. 25, 3110–3122 (2006).
  CAS PubMed PubMed Central Google Scholar
• Pasini, D., Bracken, A. P., Hansen, J. B., Capillo, M. & Helin, K. The polycomb group protein Suz12 is required for embryonic stem cell differentiation. Mol. Cell. Biol. 27, 3769–3779 (2007).
  CAS PubMed PubMed Central Google Scholar
• Strahl, B. D. & Allis, C. D. The language of covalent histone modifications. Nature 403, 41–45 (2000).
  CAS PubMed Google Scholar
• Vignali, M., Hassan, A. H., Neely, K. E. & Workman, J. L. ATP-dependent chromatin-remodeling complexes. Mol. Cell. Biol. 20, 1899–1910 (2000).
  CAS PubMed PubMed Central Google Scholar
• Santos-Rosa, H. et al. Active genes are tri-methylated at K4 of histone H3. Nature 419, 407–411 (2002).
  CAS PubMed Google Scholar
• Milne, T. A. et al. MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol. Cell 10, 1107–1117 (2002).
  CAS PubMed Google Scholar
• Dou, Y. et al. Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF. Cell 121, 873–885 (2005).
  CAS PubMed Google Scholar
• Petruk, S. et al. Trithorax and dCBP acting in a complex to maintain expression of a homeotic gene. Science 294, 1331–1334 (2001).
  CAS PubMed Google Scholar
• Bernstein, B. E. et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125, 315–326 (2006).
  CAS PubMed Google Scholar
• Ezhkova, E. et al. Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells. Cell 136, 1122–1135 (2009).
  CAS PubMed PubMed Central Google Scholar
• Sif, S. ATP-dependent nucleosome remodeling complexes: enzymes tailored to deal with chromatin. J. Cell. Biochem. 91, 1087–1098 (2004).
  CAS PubMed Google Scholar
• Smith, C. L. & Peterson, C. L. ATP-dependent chromatin remodeling. Curr. Top. Dev. Biol. 65, 115–148 (2005).
  CAS PubMed Google Scholar
• Tamkun, J. W. et al. brahma: a regulator of Drosophila homeotic genes structurally related to the yeast transcriptional activator SNF2/SWI2. Cell 68, 561–572 (1992).
  CAS PubMed Google Scholar
• Kruger, W. et al. Amino acid substitutions in the structured domains of histones H3 and H4 partially relieve the requirement of the yeast SWI/SNF complex for transcription. Genes Dev. 9, 2770–2779 (1995).
  CAS Google Scholar
• Recht, J. & Osley, M. A. Mutations in both the structured domain and N-terminus of histone H2B bypass the requirement for Swi-Snf in yeast. EMBO J. 18, 229–240 (1999).
  CAS PubMed PubMed Central Google Scholar
• Eisen, J. A., Sweder, K. S. & Hanawalt, P. C. Evolution of the SNF2 family of proteins: subfamilies with distinct sequences and functions. Nucleic Acids Res. 23, 2715–2723 (1995).
  CAS PubMed PubMed Central Google Scholar
• Corey, L. L., Weirich, C. S., Benjamin, I. J. & Kingston, R. E. Localized recruitment of a chromatin-remodeling activity by an activator in vivo drives transcriptional elongation. Genes Dev. 17, 1392–1401 (2003).
  CAS PubMed PubMed Central Google Scholar
• Sudarsanam, P., Iyer, V. R., Brown, P. O. & Winston, F. Whole-genome expression analysis of snf/swi mutants of Saccharomyces cerevisiae. Proc. Natl Acad. Sci. USA 97, 3364–3369 (2000).
  CAS PubMed PubMed Central Google Scholar
• Schnitzler, G., Sif, S. & Kingston, R. E. Human SWI/SNF interconverts a nucleosome between its base state and a stable remodeled state. Cell 94, 17–27 (1998).
  CAS PubMed Google Scholar
• Imbalzano, A. N., Kwon, H., Green, M. R. & Kingston, R. E. Facilitated binding of TATA-binding protein to nucleosomal DNA. Nature 370, 481–485 (1994).
  CAS PubMed Google Scholar
• Wysocka, J. et al. A PHD finger of NURF couples histone H3 lysine 4 trimethylation with chromatin remodelling. Nature 442, 86–90 (2006). This seminal paper links covalent histone modification to chromatin remodelling.
  CAS PubMed Google Scholar
• Haupt, Y., Alexander, W. S., Barri, G., Klinken, S. P. & Adams, J. M. Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in E mu-myc transgenic mice. Cell 65, 753–763 (1991).
  CAS PubMed Google Scholar
• van Lohuizen, M. et al. Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. Cell 65, 737–752 (1991).
  CAS PubMed Google Scholar
• Bagchi, A. et al. CHD5 is a tumor suppressor at human 1p36. Cell 128, 459–475 (2007). This paper identified CHD5 as a tumour suppressor, providing the first functional evidence that members of the CHD chromatin remodelling family modulate tumorigenesis.
  CAS PubMed Google Scholar
• Collado, M. & Serrano, M. The power and the promise of oncogene-induced senescence markers. Nature Rev. Cancer 6, 472–476 (2006). This Review discusses evidence for cellular senescence as a tumour suppressive mechanism and its utility for monitoring the success of anticancer therapies.
  CAS Google Scholar
• Bruggeman, S. W. et al. Ink4a and Arf differentially affect cell proliferation and neural stem cell self-renewal in Bmi1-deficient mice. Genes Dev. 19, 1438–1443 (2005).
  CAS PubMed PubMed Central Google Scholar
• Jacobs, J. J. et al. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev. 13, 2678–2690 (1999).
  CAS PubMed PubMed Central Google Scholar
• Jacobs, J. J., Kieboom, K., Marino, S., DePinho, R. A. & van Lohuizen, M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 397, 164–168 (1999).
  CAS PubMed Google Scholar
• Gonzalez, S. et al. Oncogenic activity of Cdc6 through repression of the INK4/ARF locus. Nature 440, 702–706 (2006). This groundbreaking paper identified a cis -acting element that functions to coordinately regulate expression of the CDKN2A and CDKN2B loci, providing the first example of replication-coupled transcriptional regulation in mammals.
  CAS PubMed Google Scholar
• Sharpless, N. E. INK4a/ARF: a multifunctional tumor suppressor locus. Mutat. Res. 576, 22–38 (2005).
  CAS PubMed Google Scholar
• Bracken, A. P. et al. The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev. 21, 525–530 (2007).
  CAS PubMed PubMed Central Google Scholar
• Park, I. K. et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423, 302–305 (2003).
  CAS PubMed Google Scholar
• Molofsky, A. V. et al. Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature 425, 962–967 (2003).
  CAS PubMed PubMed Central Google Scholar
• van der Lugt, N. M. et al. Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the bmi-1 proto-oncogene. Genes Dev. 8, 757–769 (1994).
  CAS PubMed Google Scholar
• Barradas, M. et al. Histone demethylase JMJD3 contributes to epigenetic control of INK4a/ARF by oncogenic RAS. Genes Dev. 23, 1177–1182 (2009).
  CAS PubMed PubMed Central Google Scholar
• Agger, K. et al. The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4A-ARF locus in response to oncogene- and stress-induced senescence. Genes Dev. 23, 1171–1176 (2009).
  CAS PubMed PubMed Central Google Scholar
• Kwon, H., Imbalzano, A. N., Khavari, P. A., Kingston, R. E. & Green, M. R. Nucleosome disruption and enhancement of activator binding by a human SW1/SNF complex. Nature 370, 477–481 (1994). References 70 and 71 provide important mechanistic insight into PcG–TrxG-mediated chromatin dynamics in response to activated oncogenes.
  CAS PubMed Google Scholar
• Wang, W. et al. Purification and biochemical heterogeneity of the mammalian SWI-SNF complex. EMBO J. 15, 5370–5382 (1996).
  CAS PubMed PubMed Central Google Scholar
• Kia, S. K., Gorski, M. M., Giannakopoulos, S. & Verrijzer, C. P. SWI/SNF mediates polycomb eviction and epigenetic reprogramming of the INK4b-ARF-INK4a locus. Mol. Cell. Biol. 28, 3457–3464 (2008). This work demonstrates that TrxG chromatin remodelling proteins can override PcG-mediated repression in cancer cells.
  CAS PubMed PubMed Central Google Scholar
• Ae, K. et al. Chromatin remodeling factor encoded by ini1 induces G1 arrest and apoptosis in ini1-deficient cells. Oncogene 21, 3112–3120 (2002).
  CAS PubMed Google Scholar
• Versteege, I., Medjkane, S., Rouillard, D. & Delattre, O. A key role of the hSNF5/INI1 tumour suppressor in the control of the G1-S transition of the cell cycle. Oncogene 21, 6403–6412 (2002).
  CAS PubMed Google Scholar
• Betz, B. L., Strobeck, M. W., Reisman, D. N., Knudsen, E. S. & Weissman, B. E. Re-expression of hSNF5/INI1/BAF47 in pediatric tumor cells leads to G1 arrest associated with induction of p16ink4a and activation of RB. Oncogene 21, 5193–5203 (2002).
  CAS PubMed Google Scholar
• Imbalzano, A. N. & Jones, S. N. Snf5 tumor suppressor couples chromatin remodeling, checkpoint control, and chromosomal stability. Cancer Cell 7, 294–295 (2005).
  CAS PubMed Google Scholar
• Shao, Z. et al. Stabilization of chromatin structure by PRC1, a Polycomb complex. Cell 98, 37–46 (1999).
  CAS PubMed Google Scholar
• Klochendler-Yeivin, A. et al. The murine SNF5/INI1 chromatin remodeling factor is essential for embryonic development and tumor suppression. EMBO Rep. 1, 500–506 (2000).
  CAS PubMed PubMed Central Google Scholar
• Roberts, C. W., Galusha, S. A., McMenamin, M. E., Fletcher, C. D. & Orkin, S. H. Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice. Proc. Natl Acad. Sci. USA 97, 13796–13800 (2000).
  CAS PubMed PubMed Central Google Scholar
• Guidi, C. J. et al. Disruption of Ini1 leads to peri-implantation lethality and tumorigenesis in mice. Mol. Cell. Biol. 21, 3598–3603 (2001).
  CAS PubMed PubMed Central Google Scholar
• Isakoff, M. S. et al. Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation. Proc. Natl Acad. Sci. USA 102, 17745–17750 (2005).
  CAS PubMed PubMed Central Google Scholar
• Guidi, C. J. et al. Functional interaction of the retinoblastoma and Ini1/Snf5 tumor suppressors in cell growth and pituitary tumorigenesis. Cancer Res. 66, 8076–8082 (2006).
  CAS PubMed Google Scholar
• Bultman, S. J. et al. Characterization of mammary tumors from Brg1 heterozygous mice. Oncogene 27, 460–468 (2008).
  CAS PubMed Google Scholar
• Chai, J. et al. Tumor-specific cooperation of retinoblastoma protein family and Snf5 inactivation. Cancer Res. 67, 3002–3009 (2007).
  CAS PubMed Google Scholar
• Tsikitis, M., Zhang, Z., Edelman, W., Zagzag, D. & Kalpana, G. V. Genetic ablation of Cyclin D1 abrogates genesis of rhabdoid tumors resulting from Ini1 loss. Proc. Natl Acad. Sci. USA 102, 12129–12134 (2005).
  CAS PubMed PubMed Central Google Scholar
• Thompson, P. M., Gotoh, T., Kok, M., White, P. S. & Brodeur, G. M. CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system. Oncogene 22, 1002–1011 (2003).
  CAS PubMed Google Scholar
• Jacobs, J. J. & van Lohuizen, M. Polycomb repression: from cellular memory to cellular proliferation and cancer. Biochim. Biophys. Acta 1602, 151–161 (2002).
  CAS PubMed Google Scholar
• Srinivasan, S., Dorighi, K. M. & Tamkun, J. W. Drosophila Kismet regulates histone H3 lysine 27 methylation and early elongation by RNA polymerase II. PLoS Genet. 4, e1000217 (2008).
  PubMed PubMed Central Google Scholar
• Ayton, P. M. & Cleary, M. L. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene 20, 5695–5707 (2001).
  CAS PubMed Google Scholar
• Daser, A. & Rabbitts, T. H. Extending the repertoire of the mixed-lineage leukemia gene MLL in leukemogenesis. Genes Dev. 18, 965–974 (2004).
  CAS PubMed Google Scholar
• Popovic, R. & Zeleznik-Le, N. J. MLL: how complex does it get? J. Cell. Biochem. 95, 234–242 (2005).
  CAS PubMed Google Scholar
• Liu, H., Cheng, E. H. & Hsieh, J. J. Bimodal degradation of MLL by SCFSkp2 and APCCdc20 assures cell cycle execution: a critical regulatory circuit lost in leukemogenic MLL fusions. Genes Dev. 21, 2385–2398 (2007).
  CAS PubMed PubMed Central Google Scholar
• Liu, H., Takeda, S., Cheng, E. H. & Hsieh, J. J. Biphasic MLL takes helm at cell cycle control: implications in human mixed lineage leukemia. Cell Cycle 7, 428–435 (2008). References 93 and 94 discovered that MLL levels oscillate as a function of the cell cycle, and that MLL fusion proteins found in human leukaemia are resistant to this regulation.
  CAS PubMed Google Scholar
• Yokoyama, A., Kitabayashi, I., Ayton, P. M., Cleary, M. L. & Ohki, M. Leukemia proto-oncoprotein MLL is proteolytically processed into 2 fragments with opposite transcriptional properties. Blood 100, 3710–3718 (2002).
  CAS PubMed Google Scholar
• Hsieh, J. J., Cheng, E. H. & Korsmeyer, S. J. Taspase1: a threonine aspartase required for cleavage of MLL and proper HOX gene expression. Cell 115, 293–303 (2003).
  CAS PubMed Google Scholar
• Hsieh, J. J., Ernst, P., Erdjument-Bromage, H., Tempst, P. & Korsmeyer, S. J. Proteolytic cleavage of MLL generates a complex of N- and C-terminal fragments that confers protein stability and subnuclear localization. Mol. Cell. Biol. 23, 186–194 (2003).
  CAS PubMed PubMed Central Google Scholar
• Takeda, S. et al. Proteolysis of MLL family proteins is essential for taspase1-orchestrated cell cycle progression. Genes Dev. 20, 2397–2409 (2006).
  CAS PubMed PubMed Central Google Scholar
• Tyagi, S., Chabes, A. L., Wysocka, J. & Herr, W. E2F activation of S phase promoters via association with HCF-1 and the MLL family of histone H3K4 methyltransferases. Mol. Cell 27, 107–119 (2007).
  CAS PubMed Google Scholar
• Yu, B. D., Hanson, R. D., Hess, J. L., Horning, S. E. & Korsmeyer, S. J. MLL, a mammalian trithorax-group gene, functions as a transcriptional maintenance factor in morphogenesis. Proc. Natl Acad. Sci. USA 95, 10632–10636 (1998).
  CAS PubMed PubMed Central Google Scholar
• Yagi, H. et al. Growth disturbance in fetal liver hematopoiesis of Mll-mutant mice. Blood 92, 108–117 (1998).
  CAS PubMed Google Scholar
• Kroon, E. et al. Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J. 17, 3714–3725 (1998).
  CAS PubMed PubMed Central Google Scholar
• Ayton, P. M. & Cleary, M. L. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev. 17, 2298–2307 (2003).
  CAS PubMed PubMed Central Google Scholar
• Okada, Y. et al. hDOT1L links histone methylation to leukemogenesis. Cell 121, 167–178 (2005).
  CAS PubMed Google Scholar
• van Leeuwen, F., Gafken, P. R. & Gottschling, D. E. Dot1p modulates silencing in yeast by methylation of the nucleosome core. Cell 109, 745–756 (2002).
  CAS PubMed Google Scholar
• Feng, Q. et al. Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. Curr. Biol. 12, 1052–1058 (2002).
  CAS PubMed Google Scholar
• Ng, H. H. et al. Lysine methylation within the globular domain of histone H3 by Dot1 is important for telomeric silencing and Sir protein association. Genes Dev. 16, 1518–1527 (2002).
  CAS PubMed PubMed Central Google Scholar
• Munnia, A. et al. Expression, cellular distribution and protein binding of the glioma amplified sequence (GAS41), a highly conserved putative transcription factor. Oncogene 20, 4853–4863 (2001).
  CAS PubMed Google Scholar
• Park, J. H. & Roeder, R. G. GAS41 is required for repression of the p53 tumor suppressor pathway during normal cellular proliferation. Mol. Cell. Biol. 26, 4006–4016 (2006).
  CAS PubMed PubMed Central Google Scholar
• Debernardi, S. et al. The MLL fusion partner AF10 binds GAS41, a protein that interacts with the human SWI/SNF complex. Blood 99, 275–281 (2002).
  PubMed Google Scholar
• Nie, Z. et al. Novel SWI/SNF chromatin-remodeling complexes contain a mixed-lineage leukemia chromosomal translocation partner. Mol. Cell. Biol. 23, 2942–2952 (2003).
  CAS PubMed PubMed Central Google Scholar
• De Santa, F. et al. The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing. Cell 130, 1083–1094 (2007).
  CAS PubMed Google Scholar
• Lee, M. G. et al. Demethylation of H3K27 regulates polycomb recruitment and H2A ubiquitination. Science 318, 447–450 (2007).
  CAS PubMed Google Scholar
• Hoenerhoff, M. J. et al. BMI1 cooperates with H-RAS to induce an aggressive breast cancer phenotype with brain metastases. Oncogene 28, 3022–3032 (2009).
  CAS PubMed PubMed Central Google Scholar
• Lessard, J. & Sauvageau, G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 423, 255–260 (2003).
  CAS PubMed Google Scholar
• Vire, E. et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439, 871–874 (2006).
  CAS PubMed Google Scholar
• Murphy, T. M., Perry, A. S. & Lawler, M. The emergence of DNA methylation as a key modulator of aberrant cell death in prostate cancer. Endocr. Relat. Cancer 15, 11–25 (2008).
  CAS PubMed Google Scholar
• Chen, H., Tu, S. W. & Hsieh, J. T. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. J. Biol. Chem. 280, 22437–22444 (2005).
  CAS PubMed Google Scholar
• Marchion, D. & Munster, P. Development of histone deacetylase inhibitors for cancer treatment. Expert Rev. Anticancer Ther. 7, 583–598 (2007).
  CAS PubMed Google Scholar
• Mottet, D. & Castronovo, V. Histone deacetylases: target enzymes for cancer therapy. Clin. Exp. Metastasis 25, 183–189 (2008).
  CAS PubMed Google Scholar
• Fulda, S. Modulation of TRAIL-induced apoptosis by HDAC inhibitors. Curr. Cancer Drug Targets 8, 132–140 (2008).
  CAS PubMed Google Scholar
• Tan, J. et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 21, 1050–1063 (2007).
  CAS PubMed PubMed Central Google Scholar
• Klochendler-Yeivin, A., Picarsky, E. & Yaniv, M. Increased DNA damage sensitivity and apoptosis in cells lacking the Snf5/Ini1 subunit of the SWI/SNF chromatin remodeling complex. Mol. Cell. Biol. 26, 2661–2674 (2006).
  CAS PubMed PubMed Central Google Scholar
• Vries, R. G. et al. Cancer-associated mutations in chromatin remodeler hSNF5 promote chromosomal instability by compromising the mitotic checkpoint. Genes Dev. 19, 665–670 (2005).
  CAS PubMed PubMed Central Google Scholar
• Hernando, E. et al. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature 430, 797–802 (2004).
  CAS PubMed Google Scholar
• Park, J. H. et al. Mammalian SWI/SNF complexes facilitate DNA double-strand break repair by promoting γ-H2AX induction. EMBO J. 25, 3986–3997 (2006).
  CAS PubMed PubMed Central Google Scholar
• McKenna, E. S. et al. Loss of the epigenetic tumor suppressor SNF5 leads to cancer without genomic instability. Mol. Cell. Biol. 28, 6223–6233 (2008). This paper supports the concept that inactivation of TrxG chromatin remodelling proteins can substitute for genomic instability in cancer.
  CAS PubMed PubMed Central Google Scholar
• Chai, J., Charboneau, A. L., Betz, B. L. & Weissman, B. E. Loss of the hSNF5 gene concomitantly inactivates p21CIP/WAF1 and p16INK4a activity associated with replicative senescence in A204 rhabdoid tumor cells. Cancer Res. 65, 10192–10198 (2005).
  CAS PubMed Google Scholar
• Sansam, C. G. & Roberts, C. W. Epigenetics and cancer: altered chromatin remodeling via Snf5 loss leads to aberrant cell cycle regulation. Cell Cycle 5, 621–624 (2006).
  CAS PubMed Google Scholar
• Yang, X. et al. CDKN1C (p57KPI2) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells. PLoS ONE 4, e5011 (2009).
  PubMed PubMed Central Google Scholar
• Bachmann, I. M. et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J. Clin. Oncol. 24, 268–273 (2006).
  CAS PubMed Google Scholar
• Fraga, M. F. et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nature Genet. 37, 391–400 (2005).
  CAS PubMed Google Scholar
• Lin, J. C. et al. Role of nucleosomal occupancy in the epigenetic silencing of the MLH1 CpG island. Cancer Cell 12, 432–444 (2007).
  CAS PubMed PubMed Central Google Scholar
• Wang, G. G., Allis, C. D. & Chi, P. Chromatin remodeling and cancer, part I: covalent histone modifications. Trends Mol. Med. 13, 363–372 (2007).
  CAS PubMed Google Scholar
• Weber, M. et al. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nature Genet. 37, 853–862 (2005).
  CAS PubMed Google Scholar
• Richter, G. H. et al. EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc. Natl Acad. Sci. USA 106, 5324–5329 (2009).
  CAS PubMed PubMed Central Google Scholar
• Kidani, K. et al. High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas. Oral Oncol. 45, 39–46 (2009).
  CAS PubMed Google Scholar
• Kleer, C. G. et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl Acad. Sci. USA 100, 11606–11611 (2003).
  CAS PubMed PubMed Central Google Scholar
• Pietersen, A. M. et al. EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer. Breast Cancer Res. 10, R109 (2008).
  PubMed PubMed Central Google Scholar
• Sasaki, M. et al. The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma. Lab. Invest. 88, 873–882 (2008).
  CAS PubMed Google Scholar
• Yonemitsu, Y. et al. Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinoma. Hum. Pathol. 40, 1304–1311 (2009).
  CAS PubMed Google Scholar
• van Leenders, G. J. et al. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur. Urol. 52, 455–463 (2007).
  CAS PubMed Google Scholar
• Hoffmann, M. J. et al. Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B, are associated with DNA methylation changes in prostate cancer. Cancer Biol. Ther. 6, 1403–1412 (2007).
  CAS PubMed Google Scholar
• He, X. T. et al. Association between Bmi1 and clinicopathological status of esophageal squamous cell carcinoma. World J. Gastroenterol. 15, 2389–2394 (2009).
  CAS PubMed PubMed Central Google Scholar
• Leung, C. et al. Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature 428, 337–341 (2004).
  CAS PubMed Google Scholar
• Mohty, M., Yong, A. S., Szydlo, R. M., Apperley, J. F. & Melo, J. V. The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. Blood 110, 380–383 (2007).
  CAS PubMed Google Scholar
• van Galen, J. C. et al. Expression of the polycomb-group gene BMI1 is related to an unfavourable prognosis in primary nodal DLBCL. J. Clin. Pathol. 60, 167–172 (2007).
  CAS PubMed Google Scholar
• Nowak, K. et al. BMI1 is a target gene of E2F-1 and is strongly expressed in primary neuroblastomas. Nucleic Acids Res. 34, 1745–1754 (2006).
  CAS PubMed PubMed Central Google Scholar
• Shafaroudi, A. M. et al. Overexpression of BMI1, a polycomb group repressor protein, in bladder tumors: a preliminary report. Urol. J. 5, 99–105 (2008).
  PubMed Google Scholar
• Tirabosco, R., De Maglio, G., Skrap, M., Falconieri, G. & Pizzolitto, S. Expression of the Polycomb-Group protein BMI1 and correlation with p16 in astrocytomas an immunohistochemical study on 80 cases. Pathol. Res. Pract. 204, 625–631 (2008).
  PubMed Google Scholar
• Ziemin-van der Poel, S. et al. Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. Proc. Natl Acad. Sci. USA 88, 10735–10739 (1991).
  CAS PubMed PubMed Central Google Scholar
• Gu, Y. et al. The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene. Cell 71, 701–708 (1992).
  CAS PubMed Google Scholar
• Domer, P. H. et al. Acute mixed-lineage leukemia t(4;11)(q21;q23) generates an MLL-AF4 fusion product. Proc. Natl Acad. Sci. USA 90, 7884–7888 (1993).
  CAS PubMed PubMed Central Google Scholar
• Thirman, M. J. et al. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. N. Engl. J. Med. 329, 909–914 (1993).
  CAS PubMed Google Scholar
• Versteege, I. et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 394, 203–206 (1998).
  CAS PubMed Google Scholar
• Sevenet, N. et al. Spectrum of hSNF5/INI1 somatic mutations in human cancer and genotype-phenotype correlations. Hum. Mol. Genet. 8, 2359–2368 (1999).
  CAS PubMed Google Scholar
• Biegel, J. A. et al. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res. 59, 74–79 (1999).
  CAS PubMed Google Scholar
• Reisman, D. N. et al. Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs CD44 expression. Oncogene 21, 1196–1207 (2002).
  CAS PubMed Google Scholar
• Reisman, D. N., Sciarrotta, J., Wang, W., Funkhouser, W. K. & Weissman, B. E. Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis. Cancer Res. 63, 560–566 (2003).
  CAS PubMed Google Scholar
• Medina, P. P. et al. Genetic and epigenetic screening for gene alterations of the chromatin-remodeling factor, SMARCA4/BRGI, in lung tumors. Genes Chromosomes Cancer 41, 170–177 (2004).
  CAS PubMed Google Scholar
• Medina, P. P. et al. Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines. Hum. Mutat. 29, 617–622 (2008).
  CAS PubMed Google Scholar
• Gunduz, E. et al. Genetic and epigenetic alterations of BRG1 promote oral cancer development. Int. J. Oncol. 26, 201–210 (2005).
  CAS PubMed Google Scholar
• Gunduz, E. et al. Loss of heterozygosity at the 9p21–24 region and identification of BRM as a candidate tumor suppressor gene in head and neck squamous cell carcinoma. Cancer Invest. 27, 661–668 (2009).
  CAS PubMed Google Scholar
• Yamamichi, N. et al. Frequent loss of Brm expression in gastric cancer correlates with histologic features and differentiation state. Cancer Res. 67, 10727–10735 (2007).
  CAS PubMed Google Scholar
• Moloney, F. J. et al. Hotspot mutation of Brahma in non-melanoma skin cancer. J. Invest. Dermatol. 129, 1012–1015 (2009).
  CAS PubMed Google Scholar
• Brodeur, G. M., Sekhon, G. & Goldstein, M. N. Chromosomal aberrations in human neuroblastomas. Cancer 40, 2256–2263 (1977).
  CAS PubMed Google Scholar
• White, P. S. et al. A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2-36.3. Proc. Natl Acad. Sci. USA 92, 5520–5524 (1995).
  CAS PubMed PubMed Central Google Scholar
• Caron, H. et al. Chromosome bands 1p35-36 contain two distinct neuroblastoma tumor suppressor loci, one of which is imprinted. Genes Chromosomes Cancer 30, 168–174 (2001).
  CAS PubMed Google Scholar
• Godfried, M. B. et al. Lack of interstitial chromosome 1p deletions in clinically-detected neuroblastoma. Eur. J. Cancer 38, 1513–1519 (2002).
  CAS PubMed Google Scholar
• White, P. S. et al. Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma. Oncogene 24, 2684–2694 (2005).
  CAS PubMed Google Scholar
• Okawa, E. R. et al. Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas. Oncogene 27, 803–810 (2008).
  CAS PubMed Google Scholar
• Piaskowski, S. et al. GADD45A and EPB41 as tumor suppressor genes in meningioma pathogenesis. Cancer Genet. Cytogenet. 162, 63–67 (2005).
  CAS PubMed Google Scholar
• Poetsch, M., Dittberner, T. & Woenckhaus, C. Microsatellite analysis at 1p36.3 in malignant melanoma of the skin: fine mapping in search of a possible tumour suppressor gene region. Melanoma Res. 13, 29–33 (2003).
  CAS PubMed Google Scholar
• Moley, J. F. et al. Consistent association of 1p loss of heterozygosity with pheochromocytomas from patients with multiple endocrine neoplasia type 2 syndromes. Cancer Res. 52, 770–774 (1992).
  CAS PubMed Google Scholar
• Mulligan, L. M., Gardner, E., Smith, B. A., Mathew, C. G. & Ponder, B. A. Genetic events in tumour initiation and progression in multiple endocrine neoplasia type 2. Genes Chromosomes Cancer 6, 166–177 (1993).
  CAS PubMed Google Scholar
• Edstrom Elder, E. et al. Loss of heterozygosity on the short arm of chromosome 1 in pheochromocytoma and abdominal paraganglioma. World J. Surg. 26, 965–971 (2002).
  PubMed Google Scholar
• Aarts, M. et al. Microarray-based CGH of sporadic and syndrome-related pheochromocytomas using a 0.1-0.2 Mb bacterial artificial chromosome array spanning chromosome arm 1p. Genes Chromosomes Cancer 45, 83–93 (2006).
  CAS PubMed Google Scholar
• Dong, Z. et al. Identification of two contiguous minimally deleted regions on chromosome 1p36.31-p36.32 in oligodendroglial tumours. Br. J. Cancer 91, 1105–1111 (2004).
  CAS PubMed PubMed Central Google Scholar
• Felsberg, J. et al. Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. Brain Pathol. 14, 121–130 (2004).
  CAS PubMed Google Scholar
• Barbashina, V., Salazar, P., Holland, E. C., Rosenblum, M. K. & Ladanyi, M. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin. Cancer Res. 11, 1119–1128 (2005).
  CAS PubMed Google Scholar
• Mori, N. et al. Chromosome band 1p36 contains a putative tumor suppressor gene important in the evolution of chronic myelocytic leukemia. Blood 92, 3405–3409 (1998).
  CAS PubMed Google Scholar
• Melendez, B. et al. Coincidental LOH regions in mouse and humans: evidence for novel tumor suppressor loci at 9q22-q34 in non-Hodgkin's lymphomas. Leuk. Res. 27, 627–633 (2003).
  CAS PubMed Google Scholar
• Maser, R. S. et al. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 447, 966–971 (2007).
  CAS PubMed PubMed Central Google Scholar
• Kleer, C. G., Bryant, B. R., Giordano, T. J., Sobel, M. & Merino, M. J. Genetic changes in chromosomes 1p and 17p in thyroid cancer progression. Endocr. Pathol. 11, 137–143 (2000).
  CAS PubMed Google Scholar
• Zhou, C. Z., Qiu, G. Q., Zhang, F., He, L. & Peng, Z. H. Loss of heterozygosity on chromosome 1 in sporadic colorectal carcinoma. World J. Gastroenterol. 10, 1431–1435 (2004).
  CAS PubMed PubMed Central Google Scholar
• Cheung, T. H. et al. Clinicopathologic significance of loss of heterozygosity on chromosome 1 in cervical cancer. Gynecol. Oncol. 96, 510–515 (2005).
  CAS PubMed Google Scholar
• Bieche, I. et al. Two distinct regions involved in 1p deletion in human primary breast cancer. Cancer Research 53, 1990–1994 (1993).
  CAS PubMed Google Scholar
• Bieche, I., Khodja, A. & Lidereau, R. Deletion mapping of chromosomal region 1p32-pter in primary breast cancer. Genes Chromosomes Cancer 24, 255–263 (1999).
  CAS PubMed Google Scholar
• Sjoblom, T. et al. The consensus coding sequences of human breast and colorectal cancers. Science 314, 268–274 (2006).
  PubMed Google Scholar
• Gorringe, K. L. et al. Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer. Neoplasia 10, 1253–1258 (2008).
  CAS PubMed PubMed Central Google Scholar